CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the next steps for the phase 3 SOL-1 and SOL-R studies.
The studies, which are investigating Axpaxli (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration, are moving toward completion of randomization for SOL-1 and enrollment for SOL-R.
“We’ve designed these two studies not only to be complementary but to be strategic in a way that all the questions that I believe the investigators as well as the physicians will have will